TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02594085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study: NCT02430285

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Ultrasound
Description: Endoscopic Ultrasound

Intervention type: DEVICE
Group type: OTHER
Intervention: Olympus 180 series echoendoscope
Study: NCT01867424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eovist
Description: 0.1 ml/kg Eovist will be administered intravenous (IV) to each patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eovist
Description: 0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
Study: NCT01246401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
Study: NCT01935570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (ChronoMag Smart Tablet®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (Mag2® Tablet)
Study: NCT01789255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00863317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 4mg granules daily for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: table sugar as placebo daily for 14 days
Study: NCT03277794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOP-C
Description: Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Case Management Only
Description: Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
Study: NCT02756741

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALBUMIN
Description: Albumin in two different doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALBUMIN
Description: Albumin in two different doses
Study: NCT03573804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone to Supine MRI
Description: The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
Study: NCT01131078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
Study: NCT01246401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
Study: NCT01131078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
Study: NCT05528471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: To compare an iso-caloric, low fructose diet (\~5% of total energy intake (TEI); HFCS max: 10-15% of total fructose intake) to an iso-caloric, higher fructose diet (\~10% of TEI; HFCS max 20-30% of total fructose intake) in adolescents with NAFLD. The 10% higher fructose diet is part of standard of care and is NOT the intervention.
Study: NCT00044967

Intervention type: GENETIC
Intervention: microsatellite instability analysis
Study: NCT01123967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive outreach (PRO)
Description: a mailed invitation letter followed by telephone outreach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone counseling (TC)
Description: free telephone counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Description: free nicotine replacement therapy (NRT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
Study: NCT01021059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15
Description: rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
Study: NCT00507130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 0.3 mg/kg
Description: MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 1 mg/kg
Description: MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study: NCT01518309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimavanserin tartrate (ACP-103)
Description: Tablets taken once daily by mouth at 20, 40, or 60 mg doses
Study: NCT01735097

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E (200 mg, soft capsule)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E (200 mg, soft capsule)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa
Description: Nigella sativa (200 mg, soft capsule)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
Study: NCT00944580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Description: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
Study: NCT03422055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Fucoidan SPECT
Description: Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
Study: NCT02402881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered education bundle
Description: A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
Study: NCT03874104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolysed Formula containing Pre- & Probiotics
Description: Extensively Hydrolysed Formula containing Pre- and Probiotics
Study: NCT05180604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience learning programs of eHealth care
Description: The experience learning programs of eHealth care was included six sections of activities. Six activities were conducted based on eHealth literacy framework and experience learning theory to improve patients' abilities to engage in eHealth care service. The outcome indicators were eHealth literacy, patient health engagement, the acceptance of eHealth care, eHealth usage status, and their learning experience
Study: NCT00507130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 3 mg/kg
Description: MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study: NCT01105468

Intervention type: DEVICE
Intervention: Breath Collecting Unit
Description: Collect two breath gas samples per patient on one day before surgery

Intervention type: DEVICE
Intervention: Breath Collecting Unit
Description: Collect two breath gas samples per patient on one day before surgery

Intervention type: DEVICE
Intervention: Breath Collecting Unit
Description: Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
Study: NCT03288727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interviews with a psychologist
Description: an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interviews with a psychologist
Description: an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
Study: NCT05925829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF and aaPRP
Description: Stromal vascular fraction and autologous activated platelet-rich plasma
Study: NCT04587973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Dexmedetomidine
Description: Ropivacaine plus dexmedetomidine group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Ropivacaine
Description: Plain ropivacaine group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group Control
Description: Control group
Study: NCT04425694

Intervention type: DEVICE
Intervention: e-EWS system
Description: The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
Study: NCT02031107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTBS
Study: NCT00507130

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
Study: NCT02553759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actions observed
Description: Patients observed movements without realize them. After this actions, movements will be imagined by patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actions observed
Description: Patients observed movements without realize them. After this actions, movements will be imagined by patients
Study: NCT02351271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femto LDV Z8
Description: Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual capsulorhexis&lens fragmentation
Description: Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
Study: NCT00149812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Functioning Intervention
Study: NCT01650701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: • Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: • Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - CHOP
Description: six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - CVP
Description: eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab - Bendamustine
Description: six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Study: NCT01158092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with SInergy™ System
Description: Lateral branch denervation using the SInergy™ System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Treatment with physical therapy, chiropractic care, and medication
Study: NCT00005065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT01462812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Sumatriptan 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02031107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Study: NCT02923934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
Study: NCT01391559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arformoterol
Description: 15 mcg administered via nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: 50 mcg delivered vis Diskus
Study: NCT00005065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo complete surgical resection
Study: NCT04278638

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT
Description: IORT in surgery of laryngocarcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: total laryngectomy or hemilaryngectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: total laryngectomy or hemilaryngectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Description: External radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External radiotherapy
Description: External radiotherapy
Study: NCT02122250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive web-based materials
Description: Interactive web-based materials for self-management of diabetes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static web-based materials
Description: Static web-based materials
Study: NCT03878628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem cells
Description: CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
Study: NCT01154855

Intervention type: PROCEDURE
Intervention: Prophylaxis ; Gross debridement for diseased patients
Description: 1 per patient at 2nd visit lasting approximately 1 hour.

Intervention type: PROCEDURE
Intervention: Prophylaxis ; Gross debridement for diseased patients
Description: 1 per patient at 2nd visit lasting approximately 1 hour.
Study: NCT00960778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)
Description: Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)
Description: Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denicotinized cigarettes (Quest 3 cigarettes)
Description: Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: denicotinized cigarettes (Quest 3 cigarettes)
Description: Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
Study: NCT02628652

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GLOS

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOS
Study: NCT00005065

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT01770119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccination
Description: Unprotected children will be vaccinated with two MMR vaccines
Study: NCT00834925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose diltiazem
Description: Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
Study: NCT01994278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peri Clean